PPCB

Propanc Bio

• Benzinga·31m ago

  Propanc Biopharma Announces New Preclinical Data Supporting Potential Of PRP To Treat Chemotherapy Resistance In Pancreatic Cancer; PRP Monotherapy Reduced Cancer Cell Proliferation By ~50–54% And Suppressed Long-term Clonogenic Survival By Up To 59%

• Benzinga·4d ago

  Propanc Biopharma Announces 1-For-10 Reverse Stock Split, Effective Oct. 26

• NASDAQ·10/19 00:11

  Propanc Reports Preclinical Data For PRP In Chemoresistance; Phase 1 Set For Q1 '27

• Benzinga·10/16 12:45

  Propanc Biopharma Announces It Has Identified Pancreatic Proenzyme Formulation As Potential Strategy For Addressing Chemotherapy Resistance In Pancreatic Cancer

• TipRanks·10/16 12:40

  Propanc Biopharma announces new preclinical research from PRP programs

• NASDAQ·10/08 07:40

  Propanc Reports Positive Preclinical Pancreatic Cancer Data For PRP; Phase 1b Planned In Q1 2027

• TipRanks·10/07 13:20

  Propanc highlights preclinical data for PRP in pancreatic ductal adenocarcinoma

• Benzinga·10/05 21:24

  Propanc Biopharma Registers Resale Of 6,500,000 Shares Of Common Stock

• TipRanks·10/05 21:20

  Propanc Biopharma files to sell 6.5M shares of common stock for holders

• Seeking Alpha·09/29 15:25

  Propanc Biopharma, Inc. GAAP EPS of -$17.62

• Benzinga·09/29 13:46

  Propanc Biopharma Q4 EPS $(0.10)

• TipRanks·09/29 13:25

  Propanc Biopharma FY26 EPS ($17.62)

• TipRanks·09/22 12:35

  Propanc Biopharma issues comparative analysis of PRP versus ERAS-0015

• Benzinga·09/22 12:34

  Propanc Biopharma Analysis Of PRP Against Clinical Datasets From Erasca Demonstrates PRP Does Not Exhibit RAS

• Benzinga·09/16 12:33

  Propanc Biopharma Issues Comparative Analysis Of Lead Candidate PRP Against Clinical Datasets From RAS-Targeted Programs, Including Revolution Medicines’ Daraxonrasib And Erasca’s Pan-RAS Molecular Glue ERAS-0015